avocado-soybean unsaponifiable extract (ASU)(avocado-soybean unsaponifiable extract (ASU))

概要

基本信息

药物类型

中药

别名

Avocado Soybean Unsaponifiables、Avocado-Soya Unsaponifiables、아보카도-소야불검화물의추출물

+ [2]

靶点-

作用方式-

作用机制-

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

膝关节炎

非在研适应症-

原研机构

Chong Kun Dang Pharmaceutical Corp.

在研机构

Chong Kun Dang Pharmaceutical Corp.

非在研机构

UMR 1283-8199

权益机构-

最高研发阶段批准上市

首次获批日期

韩国 (2000-04-24),

膝关节炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 avocado-soybean unsaponifiable extract (ASU) 相关的临床试验

NCT01756937

/ Completed临床4期

A Six-month, Multi Center, Randomizied, Double Blind, Parallel-group,Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

Efficacy and safety of Imotun capsule in osteoarthritis of the knee

开始日期2013-01-01

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

NCT01743287

/ Completed临床4期

A Six-month, Multi Center, Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

The purpose of this study is to evaluate efficacy and safety of Imotun capsule in osteoarthritis of the knee

开始日期2012-12-01

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

100 项与 avocado-soybean unsaponifiable extract (ASU) 相关的临床结果

登录后查看更多信息

100 项与 avocado-soybean unsaponifiable extract (ASU) 相关的转化医学

登录后查看更多信息

100 项与 avocado-soybean unsaponifiable extract (ASU) 相关的专利（医药）

登录后查看更多信息

4

项与 avocado-soybean unsaponifiable extract (ASU) 相关的文献（医药）

2019-09-01·International Journal of Rheumatic Diseases

Efficacy and safety of avocado‐soybean unsaponifiables for the treatment of hip and knee osteoarthritis: A systematic review and meta‐analysis of randomized placebo‐controlled trials

Review

作者: Simental‐Mendía, Luis E. ; Peña‐Martínez, Víctor M. ; Simental‐Mendía, Mario ; Acosta‐Olivo, Carlos A. ; Sánchez‐García, Adriana ; Vilchez‐Cavazos, Félix ; Osuna‐Garate, Jorge

AbstractObjectiveWe performed a systematic review and meta‐analysis from randomized controlled trials to examine the efficacy and safety of avocado‐soybean unsaponifiables (ASU) in patients with hip or knee osteoarthritis (OA).Data sourcesMedline, SCOPUS, Web of Science, and Google Scholar databases were searched for randomized placebo‐controlled trials.Study selectionOriginal studies were randomized placebo‐controlled trials evaluating the effect of orally administered ASU on knee or hip OA symptoms using the Lequesne index, visual analog scale (VAS) and/or joint space width (JSW).Data extractionMeta‐analysis was conducted using a random‐effects model and generic inverse variance method. Heterogeneity was tested using the I2 statistic index.Data synthesisAvocado‐soybean unsaponifiables therapy had a significant reduction on pain by VAS assessment (weighted mean difference [WMD]: −9.64 mm, 95% CI: −17.43, −1.84; P = .02; I2 = 92%). A subanalysis according to the type of OA showed that ASU significantly decreased both VAS and Lequesne index in knee OA (WMD: −17.36, 95% CI: −25.91, −8.82; P < .0001; I2 = 87% and WMD: −2.33, 95% CI: −2.88, −1.78; P < .00001; I2 = 18%, respectively) but not in hip OA. Finally, ASU supplementation showed no significant differences for adverse events compared to placebo (relative risk: 1.02, 95% CI: 0.83, 1.25; P = .88; I2 = 0%).ConclusionResults of this meta‐analysis suggest a beneficial effect of ASU treatment in symptomatic knee OA but not in hip OA. Additionally, adverse events were similar in patients receiving ASU therapy or placebo.

2011-12-01·British Journal of Neurosurgery4区 · 医学

The protective effect of avocado soybean unsaponifilables on brain ischemia/reperfusion injury in rat prefrontal cortex

4区 · 医学

Article

作者: Onder Sahin ; Ahmet Songur ; Sadik Buyukbas ; Hüseyin Fidan ; Mehmet Yaman ; Olcay Eser ; Hakan Mollaoglu ; Murat Cosar

OBJECTWe investigated the protective effects of avocado/soybean unsaponifiables (ASU) on the prefrontal cortex (PFC) after global brain ischemia/reperfusion (I/R) injury in rats.METHODSRats were randomly divided into three experimental groups as follows: Group I was control rats, Group II was ischemia rats, Group III was Isch + ASU rats. Brain ischemia was produced via four-vessel occlusion model. These processes followed by reperfusion for 30 min for both II and III groups. Rats were sacrificed and their brains were removed immediately. Malondialdehyde (MDA) and superoxide dismutase (SOD) were measured in left PFC, levels of TNF-α concentration were measured in the plasma. The number of apoptotic neurons was assayed in histological samples of the right PFC.RESULTSMDA and TNF-α levels as well as the number of apoptotic neurons were observed to have decreased significantly in Group III compared to Group II, while SOD activities have been found to have increased significantly in Group III in comparison to Group II, significantly.CONCLUSIONSWe think that ASU might have an antioxidant and neuroprotective effects in brain I/R injured rats.

2008-04-01·Osteoarthritis and Cartilage2区 · 医学

Symptomatic efficacy of avocado–soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials

2区 · 医学

Review

作者: H. Bliddal ; R. Christensen ; A. Astrup ; E.M. Bartels

OBJECTIVETo evaluate the efficacy of preparations with avocado-soybean unsaponifiables (ASUs) in osteoarthritis (OA) patients using meta-analysis on randomized controlled trials (RCTs).METHODRCTs from systematic searches were included if they explicitly stated that hip and/or knee OA patients were randomized to either ASU or placebo. The co-primary outcome was reduction in pain and Lequesne index, leading to effect size (ES), calculated as the standardized mean difference. As secondary analysis, the number of responders to therapy was analyzed as odds ratios (ORs). Restricted maximum likelihood methods were applied for the meta-analyses, using mixed effects models.RESULTSFour trials--all supported by the manufacturer--were included, with 664 OA patients with either hip (41.4%) or knee (58.6%) OA allocated to either 300 mg ASU (336) or placebo (328). Average trial duration was 6 months (range: 3-12 months). Though based on heterogeneous results, the combined pain reduction favored ASU (I(2) = 83.5%, ES = 0.39 [95% confidence intervals: 0.01-0.76], P=0.04). Applying the Lequesne index also favored ASU (I(2) = 61.0%, ES = 0.45 [0.21-0.70], P = 0.0003). Secondarily, the number of responders following ASU compared to placebo (OR = 2.19, P = 0.007) corresponded to a number needed to treat of six (4-21) patients.CONCLUSIONSBased on the available evidence, patients may be recommended to give ASU a chance for e.g., 3 months. Meta-analysis data support better chances of success in patients with knee OA than in those with hip OA.

100 项与 avocado-soybean unsaponifiable extract (ASU) 相关的药物交易

登录后查看更多信息